Investors believe that Teva overpaid for Allergan’s generic business. Teva paid $41 billion in the deal, which is set to close later this month. Some investors believe that Teva overpaid by as much as 25 percent. With regulators stepping up pressure on generics pricing, some analysts believe Teva won’t be able to extract as much value from Allergan’s generics as previously thought. Still, some proponents of the deal see greater synergy and stronger negotiating power as reasons to continue to back the acquisition.